By Tony Fong

NEW YORK (GenomeWeb News) – On the heels of data from a clinical validation study indicating its thyroid cancer test can classify fine needle aspirates as benign with high accuracy, Veracyte said this week it is on schedule to initiate commercialization of the test later this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.